Volume 43, Issue 2 pp. 227-234
ORIGINAL ARTICLE

MicroRNAs in urine as diagnostic biomarkers for multiple myeloma

Jia Li

Jia Li

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Search for more papers by this author
Chengbin Wang

Chengbin Wang

Medical Laboratory Center, The First Medical Center of Chinese PLA General Hospital, Beijing, China

Search for more papers by this author
Qian Meng

Qian Meng

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Search for more papers by this author
Zhiying Hu

Zhiying Hu

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Search for more papers by this author
Mei Hu

Mei Hu

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Search for more papers by this author
Man Zhang

Corresponding Author

Man Zhang

Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China

Clinical Laboratory Medicine, Peking University Ninth School of Clinical Medicine, Beijing, China

Correspondence

Man Zhang, Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Email: [email protected]

Search for more papers by this author
First published: 17 October 2020
Citations: 7

Abstract

Introduction

Multiple myeloma (MM) is a hematological malignancy. It is of great clinical significance to screen microRNAs (miRNAs) in urine as noninvasive diagnostic biomarkers for MM.

Methods

Urinary miRNAs in MM were performed by Agilent Bioanalyzer 2100 and verified by quantitative real-time PCR (qRT-PCR). Receiver operator characteristic (ROC) was used to evaluate the diagnostic value of abnormal miRNAs for MM. Progression-free survival (PFS) of MM was calculated by Kaplan-Meier.

Results

In microarray analysis, twelve down-regulated miRNAs dysregulated in MM. The expression levels of miR-134-5p, miR-6500-5p, miR-548q, and miR-548y were validated. These miRNAs were significantly lower in MM (P < .05), but there was no significant difference between newly diagnosed, relapse, and remission group of MM (P> .05). ROC curve analysis showed that the sensitivity of miR-134-5p, miR-6500-5p, miR-548q, and miR-548y to MM was 91.7%, 100%, 100%, and 91.7%, and the specificity was 66.7%, 75.0%, 75.0%, and 100%, respectively. The four miRNAs were negatively correlated with the total urinary light chain (r = −0.427 P = .030, r = −0.461 P = .018, r = −0.469 P = .016, r = −0.493 P = .011). In addition, miR-134-5p, miR-6500-5p, and miR-548q were positively correlated with serum ALB (r = 0.518 P = .006, r = 0.400 P = .039,r = 0.492 P = .009). The expression level of miRNAs had no significant influence on PFS in MM patients (P> .05).

Conclusion

The results show that miR-134-5p, miR-6500-5p, miR-548q, and miR-548y are potential noninvasive diagnostic biomarkers for MM.

CONFLICT OF INTEREST

The authors declare that no conflict of interest exists.

DATA AVAILABILITY STATEMENT

All data generated or analyzed to support the findings of this study are included within the article. These data are available from the corresponding author on reasonable request. Previously reported data were used to support this study and are available at [https://doi.org/10.1002/jcla.23233]. These prior studies are cited at relevant places within the text as references.11

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.